Media Contact: Nola Gruneisen
ALEXANDRIA, Va. – The American Association for the Study of Liver Diseases (AASLD) has appointed Matthew R. D’Uva, FASAE, CAE, as its new chief executive officer, effective January 21, 2020.
D’Uva brings more than two decades of association management experience to AASLD, most recently as CEO of the International Association for the Study of Pain (IASP), an interdisciplinary scientific society with nearly 7,000 members in 125 countries. IASP is the world’s largest professional organization dedicated to the supporting research, education, clinical treatment and better patient outcomes for all pain conditions. As CEO, D’Uva contributed to IASP’s growth by developing and implementing a strategic plan, strengthening the organization’s financial position, launching patient engagement programs and delivering new programs to members in Africa, Asia, Europe and the Americas.
Prior to joining IASP, D’Uva served as president and chief executive officer at the Society of Consumer Affairs Professionals (SOCAP International), a professional society representing customer care and engagement professionals from leading Fortune 1000 companies.
"Members of the AASLD Governing Board were impressed by Matthew’s breadth of experience as CEO working in outreach, patient engagement and novel programs to increase member benefits. His expertise aligns with many of AASLD’s strategic initiatives. His management philosophy is consistent with the values and culture of AASLD, which have greatly contributed to the success of this organization for so many years," said Michael W. Fried, MD, FAASLD, AASLD president. "The Governing Board, and our members, are deeply indebted to Julie Deal, who adeptly served as interim CEO during this transition. Julie will maintain her role as Executive Director of AASLD Foundation."
A leader in the association management community, D’Uva is a Fellow of the American Society of Association Executives (ASAE) and a certified association executive (CAE). He is a member of ASAE’s Key Professional Associations Committee. Previously, he served as a member of the ASAE Board of Directors, ASAE Foundation Board of Directors, and chair of ASAE’s Innovation Grants Program, Innovation Task Force and Public Policy Committee. D’Uva is a past recipient of the Young and Aspiring Association Executive Award presented by Association Trends.
"I am honored to lead AASLD as the society’s next CEO, and I look forward to working with the AASLD leadership, staff and key stakeholders to advance AASLD’s strategic plan, to advance research and to improve treatment options for liver disease patients and their families," said D’Uva. "At this dynamic time in health care, I am excited to work with AASLD members and leaders to advance the science and practice of hepatology and the many opportunities to engage members globally at all stages of their careers."
About the AASLD
AASLD is the leading organization of clinicians and researchers committed to preventing and curing liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.